Honorary Keynote Speaker
  George Church, Ph.D. Professor of Genetics, Harvard Medical School and Professor of Health Sciences & Technology, Harvard and MIT
With Walter Gilbert he developed the first direct genomic sequencing method in 1984 and helped initiate the Human Genome Project in 1984 while he was a Research Scientist at newly-formed Biogen Inc. He invented the broadly-applied concepts of molecular multiplexing and tags,homologous recombination methods,and DNA array synthesizers. Technology transfer of automated sequencing & software to Genome Therapeutics Corp. resulted in the first commercial genome sequence, (the human pathogen, Helicobacter pylori) in 1994. He initiated the Personal Genome Project (PGP) in 2005 and research on synthetic biology. He is director of the U.S. Department of Energy Center on Bioenergy at Harvard & MIT and director of the National Institutes of Health (NHGRI) Center of Excellence in Genomic Science at Harvard, MIT & Washington University. He has been advisor to 22 companies, most recently co-founding (with Joseph Jacobson, Jay Keasling, and Drew Endy) Codon Devices, a biotech startup dedicated to synthetic biology and (with Chris Somerville) founding LS9, which is focused on biofuels. He is a senior editor for Nature EMBO Molecular Systems Biology.
    Plenary Session Speakers
  John Niederhuber, M.D. Executive VP & CEO, Inova Institute for Translational Research and Personalized Medicine, Inova Health System
John E. Niederhuber, M.D., recently joined Inova Health System as Executive Vice President and CEO of the Inova Institute for Translational Research and Personalized Medicine. Prior to that he served as Director of the National Cancer Institute, one of the National Institutes of Health from 2006 until July, 2010. During his tenure as NCI director, Dr. Niederhuber shaped the Nation’s investment in cancer to address areas that are likely to pay the largest health dividends. He began The Cancer Genome Atlas, an effort to comprehensively identify the genomic changes in all major cancer types and subtypes. In addition to genomic studies of cancer and work in cancer immunotherapy, programs in nanobiology, systems biology, investigations into the tumor microenvironment, cancer initiating cells, and subcellular imaging have benefited under his direction. Dr. Niederhuber is recognized by his peers as a visionary leader in oncology. He daily puts into practice his expertise as both a cancer physician and a basic research scientist. His colleagues have acknowledged his leadership and accomplishments by electing him vice president and president of the Society for Surgical Oncology and president of the Association of American Cancer Institutes. He has served as a member of C-Change (a community of executives from government, business, and the non-profit community dedicated to conquering cancer) and as a member of the CEO Roundtable on Cancer. Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Sciences, recognizing his outstanding scientific accomplishments and commitment to service in health sciences.
  Ralph Snyderman, M.D. Chancellor Emeritus, Duke University
Dr. Snyderman is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He is currently a visiting professor in the Global Health Science Center of the University of California at San Francisco. From 1989 to July 2004, he served as Chancellor for Health Affairs and Dean of the School of Medicine. During this period, he oversaw the development of the Duke University Health System, one of the few fully integrated academic health systems in the country, and served as its Chief Executive Officer. The health system provides not only leading edge care, but is also developing tomorrow's models of health care delivery. Dr. Snyderman has been a leading proponent of a new approach to health called "Prospective Care." This model envisions each individual receiving a personalized health plan based on their own risks and needs. This will give people far more control of and responsibility for their own health as well as opportunities to improve it. Prospective Care combines the best in science and technology with humanistic medical practice and relies on integrative medicine to do this. Dr. Snyderman is the recipient of numerous honors, including the highest awards in the field of inflammation research, the Lifetime Achievement Award from the Arthritis Foundation and the first Bravewell Leadership Award for outstanding achievements in the field of integrative medicine. He is a member of the Institute of Medicine and American Academy of Arts & Sciences, past chair of the Association of American Medical Colleges and immediate past president of the American Association of Physicians.

  Program Committee Honorary Chairman
  Leroy Hood, M.D., Ph.D. President, Institute for Systems Biology
Dr. Hood’s research has focused on fundamental biology (immunity, evolution, genomics) and on bringing engineering to biology through the development of five instruments; the DNA and protein sequencers and synthesizers and the ink-jet oligonucleotide synthesizer (making DNA arrays) for deciphering the various types of biological information (DNA, RNA, proteins and systems). These instruments constitute the technological foundation for modern molecular biology and genomics. He has applied these technologies to diverse fields including immunology, neurobiology, cancer biology, molecular evolution and systems medicine. Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Dr. Hood is one of only 7 (of more than 6000 members) scientists elected to all three academies (NAS, NAE and IOM). Dr. Hood has also played a role in founding more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He is currently pioneering systems medicine and the systems approach to disease and has recently cofounded the company Integrated Diagnostics—that hopefully will become a platform company for P4 medicine.
    Honorary Award Presenter
Roger D. Kornberg, Ph.D. 2006 Chemistry Nobel Laureate & Professor of Structural Biology, Stanford University School of Medicine

Kornberg studied chemistry and biochemistry, and without having to think about it, became a scientist. He graduated from Harvard University in 1967 with a Bachelors in science, and went to Stanford University for graduate work. His doctoral thesis was on the chemical nature of phospholipids. In 1972, Kornberg went to the Medical Research Council in Cambridge for postdoctoral work in X-ray crystallography. There he became interested in the X-ray patterns Aaron Klug obtained for chromatin. Using this and other experimental data, Kornberg eventually worked out the importance of histones to chromatin structure. Kornberg published his results in 1974. Kornberg stayed on staff at the MRC until 1975 when he was offered an assistant professorship at Harvard University. In 1978, he moved to Stanford University where he is now professor of structural biology. Over the past 35 years, Kornberg has published over 150 peer-reviewed research papers on phospholipid and chromatin structure, gene regulation and transcription control. His current research interest is on the overall structure of chromatin and chromosomes and how such structuring may be associated with gene repression.

    Opening Words
Edward Abrahams, Ph.D. President, Personalized Medicine Coalition

Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC). Representing a broad spectrum of academic, industrial, patient, provider and payer communities, PMC seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. It has grown from its original 18 founding members in November 2004 to over 175 today. Previously Dr. Abrahams was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University. Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for the House Committee on the Interior. The author of numerous essays, Dr. Abrahams serves as senior editor of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.  

Stephen J. Galli, M.D. Chair and Professor of Pathology, Professor of Microbiology and Immunology, Mary Hewitt Loveless, MD Professor, Chief of Pathology, Stanford Hospital & Clinics; Co-Director, Stanford Center for Genomics and Personalized Medicine

Galli received his BA and MD from Harvard, trained in Pathology at Massachusetts General Hospital, and then served on the Harvard faculty until moving to Stanford as Chair of Pathology in 1999. Galli investigates the roles of mast cells in health and disease, including allergies and asthma. Dr. Galli was President of the American Society for Investigative Pathology (2005-2006) and has been elected to several honorary societies including the Collegium Internationale Allergologicum (his four year term as President began in 2010), the Institute of Medicine of the U.S. National Academy of Sciences, and the Accademia Nazionale dei Lincei in Rome (considered the oldest secular scientific society in the Western world), and is an Honorary Fellow of the College of American Pathologists. In 2006-2007, the last year of a three year elected term, Dr. Galli was the Chair of the Advisory Board to the President and Provost of Stanford University.  

    Program Committee
Michael D. Amos, Ph.D. Biosciences Advisor to the Director of the Chemical Science and Technology Laboratory, National Institute of Standards and Technology (NIST), Technology Administration, U.S. Department of Commerce
Dr. Michael D. Amos has held various industry research, marketing and business development positions in the fields of biopharmaceuticals, neutraceuticals, drug delivery, transgenics, immunodiagnostics, molecular biology and molecular pathology. He is also a founder of two biotechnology companies. Dr. Amos joined NIST in 2002 as a Program Manager and Biologist in the Chemistry and Life Sciences Office of the Advanced Technology Program (ATP), an extramural funding arm of NIST. Mike joined CSTL in 2006, and serves as biosciences advisor to Dr. Willie May as a liaison to industry, academia and other government agencies in the bioscience and health care areas. Dr. Amos serves as the Department of Commerce representative on the Department of Health and Human Services Secretary’s Advisory Committee on Genetic, Health and Society (SACGHS). Dr. Amos is a leader in the field of autoimmune immunodiagnostics and serves on the Autoimmune Disease Coordinating Committee of the National Institutes of Health.
  Amos Barzilay Program Committee Chairman, Personalized Medicine World Conference
Until recently, Dr. Barzilay was the interim CEO of CollaBrx, a biotechnology company whose goal is to help oncologists develop customized therapies for cancer patients who are unresponsive to standard treatments.  Dr. Barzilay is a Venture Consultant and was a General Partner with Walden International, a global Venture Capital firm with over $2 billion under management. At Walden, Dr. Barzilay led several investments in innovative software companies and served on their boards. Prior to Walden, Dr. Barzilay was Vice President & General Manager, Content and Supplier Solutions in Commerce One. Dr. Barzilay joined Commerce One as part of Commerce One's acquisition of Mergent Systems. Dr. Barzilay was a co-founder, chairman, and CEO of Mergent Systems, a business-to-business e-commerce infrastructure start-up. Prior to Mergent, Dr. Barzilay held a variety of senior management positions including General Manager of C*ATS,  senior marketing executive at Informix and CEO at Syntelligence Systems. Prior to Syntelligence, Dr. Barzilay was an AI researcher at Xerox Parc. Dr. Barzilay has an engineering degree from the Technion in Israel and an M.B.A. and Ph.D. degree from the University of Pittsburgh.
  Yuval Bar-Or President & CEO, GeneMark, Inc.; Chairman, Steering Committee, Personalized Medicine World Conference
Yuval Bar-Or is a serial entrepreneur who has managed emerging biotech and technology companies for over 20 years. He is founder, President and CEO of GeneMark, a provider of innovative somatic mutation detection assays for guiding targeted anti-cancer therapies. Prior to GeneMark, he was founder, President, CEO and a member of the Board of Probix, an enterprise information security solution provider. He led the company from inception, through product development, commercialization, and to product deployment at Global Fortune 2000 companies. Probix was acquired by Heisei Denden Corporation, a Japanese teleco provider. Prior to Probix, he was Vice President, New Technology, at Cylink Corporation, where he was responsible for numerous successful and very profitable programs. In this capacity, he brought Cylink to become the undisputed network security leader. During his ten years career at Cylink, he also held engineering, marketing and business development management positions. He holds MSEE from the University of California, San Diego, and BS (Magna Cum Laude) in Applied Mathematics from Tel Aviv University.
  Tal Behar Executive Director & Founder, Personalized Medicine World Conference
Tal Behar is the Founder and Executive Director of the Personalized Medicine World Conference (PMWC). She has also been the Executive Director of Silicom Ventures, the largest angel and venture capital investor forum, since 2001. Tal founded the PMWC with the mission to enable a platform which aids in the accelerated adoption of Personalized Medicine on a global-scale. Tal has extensive experience in event organization and production. Under her leadership Silicom Ventures launched over 160 high technology events located in Silicon Valley and abroad. Tal was instrumental in helping Silicom Ventures grow from 25 to over 250 members. Tal's duties as Silicom Ventures' Executive Director involve marketing, business development, and operations - often, she is the voice of Silicom Ventures to some of the most prominent players in the investment, business and political worlds. Prior to Silicom Ventures, Tal was a Law student at Tel Aviv University in Israel. Previously she was a senior officer in the IDF for over three years.
Brett Davis Senior Director, Oracle Health Sciences

Brett Davis is a Senior Director in Oracle's Health Sciences Global Business Unit.  In this role, Brett is responsible for shaping and driving Oracle's personalized healthcare strategy and solutions.  He works closely with leaders in healthcare and life sciences to help them leverage innovative information technologies and applications to innovate and grow.  In addition to his role at Oracle, he is on the Board of Directors of the Personalized Medicine Coalition, served on the US Department of Health and Human Services HRSA’s Genetic Services Policy Project Advisory Panel, is a Strategic Advisor for the Ben and Catherine Ivy Foundation for glioma research, and has been an invited speaker at industry meetings on information technology’s transformative role in the health sciences. Prior to joining Oracle, Brett was a Business Unit Executive in IBM's Healthcare and Life Sciences business.  In this role, he was involved in helping shape IBM’s strategy for health analytics, clinical genomics, high performance scientific computing, biobanking and translational medicine. Prior to joining IBM, Brett led business development and marketing efforts at Genstruct, Inc., a Cambridge, MA based biotech.  Previously he served as Senior Product Manager and Director of Marketing for Viaken Systems, Inc., where he helped develop and market bioinformatics and knowledge management solutions for pharmaceutical research. 

  Sue Siegel Partner, Mohr Davidow Ventures
Sue Siegel is a Partner at Mohr Davidow Ventures, a top-tier Silicon Valley venture firm. She leads investments in companies focused on personalized medicine, enabling platform technologies for biomedical research, and innovative healthcare companies with disruptive business models. Prior to joining MDV, Sue was President and Director of Affymetrix, Inc., (NASDAQ: AFFX) a company that pioneered GeneChip® technology, which helped accelerate the advent of personalized medicine in modern medicine. Sue serves on the board of directors of Pacific Biosciences, Navigenics, Crescendo Biosciences, Corventis, RainDance Technologies and On-Q-ity. As a member of the Presidents’ Circle of the National Academies, Sue serves as an advisor to the Institute of Medicine. She is board member emeritus of The Silicon Valley Tech Museum, serves on The Gladstone Institutes Advisory Council and the Stanford ITI Council, is a YPO member, and a Henry Crown Fellow of the Aspen Institute. As part of the Crown Fellowship, Sue and her husband co-founded with Stanford Hospital, Checking-In™, an organization dedicated to serving our aging population.
Patrick Terry Principal of Pricing and Reimbursement/Market Access Practice, Scientia Advisors, Co-founder of Personalized Medicine Coalition
Patrick F. Terry was recently appointed as Principal of Pricing and Reimbursement/Market Access Practice at Scientia Advisors. Terry is a social entrepreneur who has founded a series of philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. He co-founded Genomic Health [NASDAQ: GHDX] and was former Director at the pioneering personalized medicine company based in California. He has published dozens of peer-reviewed scientific papers, articles, and book chapters in the fields of genetics, rare disease, and personalized medicine. Some of his recent activities included leadership positions on numerous trade associations, professional societies, corporate boards, and federal advisory bodies. He has experience coordinating genetics research, conducting research on rare diseases, and managing a life sciences patent portfolio. He has received many honors and awards in the business and scientific communities in the U.S. and internationally. He is currently a Director at Sirius Genomics, TcLand Expression, BioLogos Foundation, and GRAND Therapeutics. Patrick has also helped found the following organizations: Personalized Medicine Coalition, 21st Century Medicine Coalition, PXE International, Genetic Alliance BioBank, International Genetic Alliance, European Personalized Medicine Diagnostic Association, and GRAND Therapeutics.
  Yael Weiss, M.D., Ph.D. Licensing & External Research, Merck & Co., Inc.
Dr. Weiss completed her MSc and PhD in molecular genetics at the Weizmann Institute of Science, Rehovot, Israel and obtained her medical degree at Hadassah Medical Center, affiliated with The Hebrew University of Jerusalem, Israel. After practicing medicine for a few years, Dr. Weiss joined an Israeli venture capital firm as a vice president responsible for analyzing and maintaining deal flow, and then moved on to become a medical and business development director at Genzyme Israel. Dr. Weiss joined Merck's Israeli subsidiary as medical director in the beginning of 2004 and this summer joined Merck's Licensing group in San Francisco as a scientific scout responsible for identification of licensing opportunities emanating from the West Coast.
Master of Ceremonies
  David Ewing Duncan Author, Experimental Man
David Ewing Duncan is an award-winning, best-selling author of seven books and numerous essays, articles and short stories; and a television, radio and film producer and correspondent. He writes columns for Fortune and for MIT Technology Review, and is the Chief Correspondent for public radio's "Biotech Nation". He writes for the New York Times, Wired, Discover, National Geographic, and many other publications. At UC Berkeley he is the Director of the Center for Life Science Policy and a Visiting Researcher at the Graduate School of Journalism. David's most recent book is the bestselling Experimental Man: What One Man's Body Reveals About His Future, Your Health, And Our Toxic World (Wiley). His previous book was Masterminds: Genius, DNA and the Quest to Rewrite Life (Harper Perennial). He wrote the international bestseller Calendar: Humanity's Epic Struggle to Determine a True and Accurate Year (Harper-Collins/Avon), published in 19 languages, and a bestseller in 14 countries.
  Andrew Schorr Founder, Patient Power
Andrew Schorr is a respected medical journalist and online broadcaster who is a patient himself, a 14-year chronic lymphocytic leukemia survivor. Andrew participated in a phase II clinical trial for a 3-drug combination (chemotherapy+Rituxan) and it has led to a 10 year deep remission. He is a strong advocate for participation in clinical trials and founder and host of programs on www.patientpower.info on the latest treatments and research. Patient Power's sponsors include M.D. Anderson Cancer Center, Penn Medicine, University of Washington, UCSF Medical Center, Genentech, Amgen, and BioMarin.
  Keith B. Strier Principal, Health Sciences & Government, Deloitte LLP
Keith Strier is a Principal/Partner with Health Sciences & Government Practice of Deloitte LLP and serves in numerous roles including Co-Leader, Health Informatics and Senior Fellow in Deloitte’s Washington, DC-based healthcare think tank, Center for Health Solutions. Keith advises Ministries of Health and Multi-National Corporations alike on biomedical innovation, personalized healthcare, translational medicine and globalization themes such as medical tourism and cross-border collaboration. Keith has been a Guest Faculty at the Harvard Medical School / MIT Health Science Technology Program, lecturing on healthcare innovation, since 2002. He also serves as a Strategic Advisor to Harvard Medical School’s Center for BioMedical Informatics. Keith has been a guest speaker at many prominent US academic institutions, including UCLA’s LA BioMedical Research Institute, UC Irvine’s Healthcare MBA Program, USC’s Global BioBusiness Initiative, UC Berkeley’s BioExec Institute, Claremont’s Keck School of Applied Sciences and at the Mayo Clinic’s Inaugural Symposium on Innovation in Healthcare. Internationally, Keith has been an invited speaker at the Summit on Information Systems in Translational Research at Seoul National University in Seoul, South Korea (2008), at Peking Union Medical Center in Beijing, China (2009) and at Amgen’s 2nd annual Oncology and Hematology Conference in Istanbul, Turkey (2010). Mr. Strier has a Bachelor’s of Science in Industrial & Labor Relations with Honors from Cornell University (1993) and a Law Degree from New York University’s School of Law (1996).
    Speakers and Panelists
  Bonnie J. Addario President, Founder & Chair, Bonnie J. Addario Lung Cancer Foundation

Bonnie is the Founder and Chair of the Bonnie J. Addario Lung Cancer Foundation, a San-Francisco-based nonprofit organization that is the nation’s largest philanthropy devoted exclusively to eradicating lung cancer. With unanimous support from the United States Senate to make lung cancer a national priority, Bonnie works collaboratively with a diverse group of physicians, researchers, corporations, legislators, and individuals to identify solutions and make timely and meaningful change through research, early detection, education, prevention, and treatment. Bonnie is a 6- year lung cancer survivor and a visionary with 25 years of experience in managing a large oil company and a commercial credit card networking company. A nationally recognized business leader, from 1997 to 2004, Bonnie was the President of both the Commercial Fueling Network and Olympian Oil companies. Bonnie was the first female President of the California Independent Oil Marketers. Bonnie is the founder of the Addario Lung Cancer Medical Institute (ALCMI), serves as a past director of the Sequoia Hospital Foundation Board, Vice Chair of the University of California, San Francisco (UCSF) Thoracic Cabinet, and is an advocate and member of Southwest Oncology Group (SWOG) Lung Committee.

  Mara Aspinall CEO, On-Q-ity, Inc.
Mara G. Aspinall is President and CEO of On-Q-ity, Inc. an innovative diagnostics company focused on informing and transforming the cancer patients' treatment cycle through circulating tumor cell diagnostics. For the past seven years she was President of Genzyme Genetics, a leading provider of testing services in the oncology and reproductive markets, Prior to that, Mara was President of Genzyme Pharmaceuticals and began her business career with Bain & Company. Mara has an appointment as Lecturer in Health Care Policy at Harvard Medical School, serves as a Board member of Blue Cross/Blue Shield of Massachusetts, Vice Chairman of the Personalized Medicine Coalition, and is a member of the federal HHS Secretary's Advisory Committee on Genetics, Health and Society.
  Beth Anne Baber, Ph.D. CEO and Co-founder, The Nicholas Conor Institute
Beth Anne is currently the CEO and co-founder of the The Nicholas Conor Institute and has more than 20 years of academic experience in molecular biology, neurobiology and physiology, cell biology, developmental biology, cancer biology, and signal transduction. Her current research focuses on the understanding of the molecular mechanisms involved in DNA damage repair following treatment with radiation and chemotherapeutic agents. Her work in DNA damage signaling has led to publications in major scientific journals, including Nature and Science. The National Institute of Health, the Leukemia and Lymphoma Society and the Beckman Laser Institute funded her research initiatives at the Salk Institute. Beth Anne received her Ph.D. in Macromolecular Cellular Structure and Chemistry from The Scripps Research Institute. She is the 2007 DLA Piper-Athena FlexMBA Scholarship recipient and received her M.B.A. from the University of California-San Diego Rady School of Management in August 2009.
  Nir Barzilai, M.D. Albert Einstein College of Medicine
Dr. Barzilai was the chief medic of the Israeli army before enrolling in the Israel Institute of Technology Medical School (M.D. 1985). His residency was in Medicine and Geriatrics at Hadassah Hospital (Hebrew University) and at Yale University. Dr. Barzilai then trained in Endocrinology and Molecular Biology at Cornell University Medical College and at The Albert Einstein College of Medicine.  Dr. Barzilai is the Director of the Institute for Aging Research at the Albert Einstein College of Medicine. He is currently an Associate Professor in the Department of Medicine and the Diabetes Research Center and is a member of the Divisions of Endocrinology and Geriatrics. He is also the Director of the Montefiore Hospital Diabetes Clinic.  He was the recipient of the prestigious Beeson Fellow for Aging Research and the Senior Ellison Foundation award. He is supported by numerous grants (NIH, American Federation of Aging Research, The Ellison Medical Foundation, and The Albert Einstein College of Medicine) to investigate the reasons for the deterioration of glucose homeostasis with aging as well as to search for human longevity genes. Dr. Barzilai has published nearly 90 peer-reviewed papers, reviews and chapters in textbooks.
  Paul Billings, M.D. Chief Medical Officer, LIFE Technologies
Dr. Paul R. Billings is the first Chief Medical Officer of LIFE Technologies, a world leader in providing nucleic acid and other analytic tools for biomedical research and the delivery of personalized medicine. Prior to joining LIFE, Dr. Billings was the founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital in Mountain View, CA. From 2007-2009, Dr. Billings served as President, Chief Executive Officer and Director of CELLective Dx Corporation, a company sought to revolutionize cancer care through the provision of microfluidic products and services focused on circulating tumor cells. For five years until 2007, he was Senior Vice President and Senior Geneticist at Laboratory Corporation of America Holdings Inc (LH).Prior to joining LH, Dr. Billings was Deputy Chief of Staff and Chief of General Internal Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. Dr. Billings graduated with an AB in History summa cum laude from UC San Diego, received both his MD and PhD degrees from Harvard University.

Steven R. Binder Technology Development Clinical Diagnostic Group Bio-Rad Laboratories

Steven R. Binder is the Director of Technology Development for the Clinical Diagnostic Group at Bio-Rad Laboratories, a position he has held since 2000. His work involves the evaluation of novel technologies for clinical diagnostics, as well as new biomarkers. After receiving a B.A. in History and Science from Harvard University, Steve worked in hospitals as a clinical chemistry supervisor and as a methods development specialist. He joined Bio-Rad in 1983, where he developed clinical chromatography methods for fifteen years. Since 1998, Steve has been occupied with the technology of protein arrays, especially autoimmune biomarkers and methods. His current interests include autoantibodies for diagnosis and monitoring of cancer. He has authored over 20 papers in peer-reviewed journals and has received 10 US patents, which include his work on pattern recognition methods. Steve serves on the editorial board of IVD Technology magazine.
  Alexis Borisy CEO and President, Foundation Medicine, Inc.
Alexis Borisy is a successful biotechnology entrepreneur with over 15 years of experience building and operating innovative science based organizations. Alexis joined Third Rock Ventures in 2009 as an Entrepreneur-in-Residence and focuses on the formation, development and strategy of new companies. Prior to joining Third Rock Ventures, Alexis founded CombinatoRx in 2000, serving as its CEO, and bringing the company public on the NASDAQ in an IPO. He has raised $750 million in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Borisy was honored as the MIT Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar. Borisy's undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Borisy serves on the Board of the Biotechnology Industry Organization, is an Overseer at the Boston Museum of Science, and is the Chairman of Forma Therapeutics. Borisy is currently the founding CEO of a new venture.
  Brian Buxton Principal and Co-founder, Easton Associates, LLC
Brian Buxton is a Principal and co-founder at Easton Associates, LLC, a management consulting firm in New York City, where he manages projects in the in vitro diagnostics, molecular diagnostics and clinical laboratory services segments, as well as in pharmaceuticals and medical devices. His current area of focus is assisting pharmaceutical and diagnostics companies in developing effective partnerships for clinical trial biomarkers and companion diagnostic tests to assist in the selection of therapies. He has worked in the diagnostics and clinical laboratory testing industries since 1980. Previously, he was Senior Consultant with The Wilkerson Group, and prior to that, headed business development at MetPath and Unilab (now Quest Diagnostics). He holds an MBA with High Distinction (Baker Scholar) from Harvard Business School and a BA in Philosophy (Phi Beta Kappa) from the University of North Carolina at Chapel Hill.
  Brook Byers Partner KPCB
Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. Brook was President and a Director of the Western Association of Venture Capitalists. He is a currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford’s Bio-X Advisory Council and the Stanford Eye Council. In 2007, he was awarded the “UCSF Medal” as their honorary degree equivalent. In 2008, he was elected a Fellow of the American Academy of Arts and Sciences. In 2009, he received the Lifetime Achievement Award from the National Venture Capital Association. In May, 2010, he received an Honorary Ph.D. from Georgia Tech.
  Michael F. Christman, Ph.D. President and CEO, Coriell Institute for Medical Research
Michael F. Christman, Ph.D., is the President and Chief Executive Officer of the Coriell Institute for Medical Research. After taking the helm of the Coriell Institute in 2007, Dr. Christman established the Coriell Personalized Medicine Collaborative® (CPMC®): an evidence-based research study with the goal of determining the utility of using genome information in health management and clinical decision-making, as well as to discover presently unknown gene variants that elevate one’s risk of complex disease and affect one’s response to medications. Dr. Christman previously served as professor and founding chair of the Department of Genetics and Genomics for Boston University School of Medicine. Recently, Dr. Christman and other Coriell scientists collaborated with Dr. Charles Rotimi of the NIH to complete the largest genome-wide association study for hypertension and blood pressure in an African American population to date. Dr. Christman received his bachelor’s degree in chemistry with honors from the University of North Carolina, Chapel Hill, and a doctorate in biochemistry from the University of California, Berkeley. Dr. Christman has published articles in scientific journals such as Science, Nature and Cell, and his work has been described in the NY Times, Wall Street Journal and other media.
Felix Frueh, Ph.D. Personalized Medicine VP and R&D, Medco Health Solutions, Inc.
Dr. Felix Frueh joined Medco in May 2008 to lead Medco’s personalized medicine research and development organization. In this function, Dr. Frueh manages Medco’s expanding research efforts in personalized medicine, leveraging the newest developments in science to improve the safety and efficacy of prescription drug care. He is also responsible for the development of Medco’s Personalized Medicine Research Center, which is under construction in Whitestown, Indiana. Prior to joining Medco, Dr. Frueh was Associate Director for Genomics at the U.S. Food and Drug Administration (FDA), where he built and led a core genomics review team in the Center for Drug Evaluation and Research (CDER), and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group (IPRG). Prior to the FDA, he was Managing Partner at Stepoutside Consulting, LLC, and held senior positions at Transgenomic and Protogene Laboratories. Dr. Frueh’s academic career includes a faculty appointment at the Departments of Pharmacology and Medicine at Georgetown University in Washington DC, and postdoctoral fellowships at Stanford University and the University of Basel, Switzerland, where he also received his Ph.D. in biochemistry.
  Jeffrey N. Gibbs Director, Hyman, Phelps & McNamara, P.C.
Jeffrey N. Gibbs is a director in the Washington, D.C. law firm of Hyman, Phelps & McNamara, PC. Before entering private practice, he was Associate Chief Counsel for Enforcement at the Food and Drug Administration.  Jeff also served as a Special Assistant United States Attorney in the District of Columbia in the Civil Division.  He is currently a member of a university Institutional Review Board and General Counsel to the Food and Drug Law Institute. Jeff assists medical device and pharmaceutical companies with a variety of regulatory issues, including FDA product approval, product labeling, clinical studies, promotional and marketing programs, FDA enforcement actions, and product liability counseling.  He has written extensively on FDA issues, including those involving diagnostic products, and has advised IVD companies on a wide range of regulatory issues.  He is a member of the editorial advisory board of In Vitro Diagnostic Technology, and is General Counsel of the Food and Drug Law Institute. Jeff graduated from Princeton University and New York University School of Law.
  Mary Haak-Frendscho, Ph.D. President and CSO, Takeda Pharmaceuticals San Francisco
Mary Haak-Frendscho is President and Chief Scientific Officer of Takeda San Francisco, responsible for establishing Takeda's new center of excellence for biologics, which also serves as the therapeutic antibody IND engine for Takeda Pharmaceuticals. Dr. Haak-Frendscho leads the overall discovery and preclinical development, as well as actively expanding Takeda's US science, business, and intellectual property presence.   She has nearly 20 years of biopharmaceutical and biotechnology experience, is an inventor on over 25 issued and pending patents, authored about 70 scientific articles, and has an adjunct appointment at the University of Wisconsin.

Garret Hampton, Ph.D. Senior Director and Head of Oncology Biomarker, Development Research and Early Development (gRED) Group, Genentech

Dr. Hampton is a graduate of Trinity College Dublin, Ireland (B.A. Honors), and Imperial Cancer Research Fund / University of London received, where he received his Ph.D. in Cancer Genetics with Sir Walter Bodmer. Following a postdoctoral fellowship at the Center for Human Genome Research at the Salk Institute for Biological Studies, La Jolla, CA, Garret served as Head, Section of Human Carcinogenesis, Ludwig Institute for Cancer Research, San Diego and Assistant Professor of Medicine at University of California San Diego. Garret moved to the biopharmaceutical sector in 1997, joining Genos Biosciences as Director of Genetics; and subsequently the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, as Director of Cancer Biology Discovery and Oncology Therapeutic Area Leader. He joined Celgene Corporations’ Research Division in February 2006 as Executive Director, Molecular Medicine, and was responsible for initiating and leading the translational sciences efforts at the San Diego, San Francisco and Summit, New Jersey, Research sites. Garret most recently joined Genentech’s Research and Early Development (gRED) Group in June 2009 as Senior Director and Head of Oncology Biomarker Development. In this role, Garret is responsible for leading the Oncology Pharmacodynamic (PD), Predictive biomarker and Companion diagnostics groups and for defining and implementing the strategy for biomarker development in oncology early development.
  Chris Hempel Founder, Addi and Cassi & Sparkpr

Chris Hempel’s six year old identical twin daughters, Addi and Cassi, are afflicted with an ultra rare a fatal cholesterol storage disorder called Niemann Pick Type C disease. Since receiving the NPC diagnosis on her twins in October 2007, Ms. Hempel has worked tirelessly with doctors and researchers around the world to search for a lifesaving treatment for her daughters. In May 2010, she worked with Children’s Hospital Oakland to receive one of the few orphan drug designations granted by the FDA for a non-toxic sugar compound called cyclodextrinPrior to becoming a full-time medical advocate for her children, Chris worked in corporate communications at the Internet company Netscape and also co-founded Sparkpr, one of the leading technology public relations companies in the country.

  Peter Hirth, Ph.D. Co-founder & CEO, Plexxikon
Dr. Hirth co-founded Plexxikon in December 2000, and has more than 25 years of biotechnology and pharmaceutical discovery and development experience. Previously, he was president of Sugen, Inc. until the sale of the company to Pharmacia Corporation in 1999. At Sugen, he helped build the company from its inception and advanced several kinase inhibitors through clinical trials for the treatment of oncology. This includes the drug Sutent®, now owned by Pfizer through its acquisition of Pharmacia. Prior to Sugen, Dr. Hirth was a vice president in research with Boehringer Mannheim where, among other responsibilities, he successfully led the company's erythropoietin program. Previously, he also was a research scientist with the Max Planck Institute, following the completion of his post doctoral work at the University of California, San Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg University, Germany.
  Kathy L. Hudson, Ph.D. Chief of Staff, Office of the Director, National Institutes of Health (NIH)
Dr. Kathy Hudson is Chief of Staff, Office of the Director, National Institutes of Health (NIH). She is also the founder and Director of the Genetics and Public Policy Center and is an Associate Professor in the Berman Bioethics Institute, Institute of Genetic Medicine, Department of Pediatrics at The Johns Hopkins University. Dr. Hudson serves on a number of advisory boards, has published articles and is a frequent speaker on issues related to biotechnology, genetics, and public policy. Before founding the Center, Dr. Hudson was the Assistant Director of the National Human Genome Research Institute (NHGRI) and was responsible for communications, legislation, planning and education activities. She provided leadership in public policy, genetic technology and public affairs issues and spearheaded efforts to prevent genetic discrimination. Previously, she served as a senior policy analyst in the Department of Health and Human Services and worked on Capitol Hill. Dr. Hudson received her PhD in Molecular Biology from the University of California at Berkeley, her MS in Microbiology from the University of Chicago, and her BA in Biology from Carleton College.
  Hartmut Juhl, M.D. CEO, Indivumed GmbH & Indivumed Inc. & Inostics GmbH
Hartmut Juhl, MD, is CEO of Indivumed GmbH and its subsidiary Indivumed Inc. and Inostics GmbH. In 2002, he founded Indivumed, GmbH in Hamburg, Germany – a company focused on promotion and development of individualized cancer therapies based on a unique clinical database and tissue collection from cancer patients. Indivumed has a subsidiary, Indivumed Inc., in the Washington DC area which is also focused on tissue and data collection. A second subsidiary of Indivumed, Inostics GmbH, was founded in 2009 with Bert Vogelstein and colleagues from Johns Hopkins University to improve DNA analysis as a basis for predicting drug response and individualizing cancer medicine. Juhl has appointments as Adjunct Professor at Georgetown University in Washington DC and the University of Hamburg in Germany.
  Paul Kearney, Ph.D. Founder, President & Chief Scientific Officer, Integrated Diagnostics
In 2008 Paul Kearney joined the Institute for Systems Biology as Scientific Director of Special Projects where he helped establish a  $100M collaboration in Personalized Medicine between ISB and the University of Luxembourg.  Previously, Dr. Kearney was VP Bioinformatics at Caprion Proteomics, a leading provider of proteomics services for biomarker discovery. At Caprion he managed technology R&D, oversaw all aspects of data analysis, IT and biomarker panel discovery and experimental design. Prior to Caprion, Dr. Kearney was co-founder and VP R&D of Bioinformatics Solutions (BSI), a provider of genomic and proteomic data analysis tools. BSI won an R&D 100 award and the CASP4 competition for its PROSPECT tool for automated protein structure prediction.  Prior to BSI, Dr. Kearney was assistant professor of Computer Science at the University of Waterloo where he was the founder and inaugural Director of the Bioinformatics Program.
  Eric Lai, Ph.D. Senior Vice President, Research & Development, Gen-Probe, Inc.
Dr. Lai joined the company in February 2009. Dr. Lai previously served as Vice President, Pharmacogentics Experimental Project Coordination and Analysis, at GlaxoSmithKline (GSK). Dr. Lai was previously GSK’s Vice President, Discovery and Pipeline Genetics. Prior to joining GSK in 1995, he was an Assistant Professor in the department of Pharmacology at the University of North Carolina at Chapel Hill. Dr. Lai earned his Ph.D. in Pharmacology and Microbiology from Columbia University and B.S. in Chemistry from the University of Waterloo in Ontario, Canada.
  Lawrence B. Leisure Managing Partner, AccelusHealth Partners, LLC
Larry Leisure is the Managing Partner of the Silicon Valley based AccelusHealth Partners and serves as a Senior Advisor to Ingenix Consulting and Venture Partner at Kleiner Perkins Caufield & Byers. He has had a distinguished career in healthcare serving in a number of senior consulting and management roles. His consulting leadership positions have included Accenture where he was the Global Managing Partner for the Health Vertical, and Towers Perrin where he led the Managed Care practice. In these roles he has served as client partner to many of the largest US health plans and PBMs including Aetna, Caremark, CIGNA, Medco, UnitedHealth, and WellPoint as well as many of the largest US employers including American Airlines, AT&T, Exxon, Proctor & Gamble, Shell Oil, Wal-Mart, and Wells Fargo Bank. From 2003 to 2007 he joined one his clients, Kaiser Permanente, where he was Senior Vice President and oversaw the sales & account management functions. He is well known industry leader and innovator. He sits on the boards of several Silicon Valley health information and bioscience companies including Crescendo Bioscience, Medpedia, Navigenics, and Tethys Bioscience. He received his AB in Economics from Stanford University and his MBA in Finance from the University of California, Los Angeles. He resides in Atherton, California with his wife Bren.
  Martin LeBlanc President and CEO, Caprion Proteomics
Martin was named President of Caprion Proteomics in March 2007 following the merger between Caprion Pharmaceuticals and Ecopia Biosciences (now Thallion Pharmaceuticals, Inc.). As co-founder of Caprion Pharmaceuticals and its Chief Operating Officer from 2000 to March 2007, Martin led the development and implementation of Caprion’s proteomics technology and business, as well as Caprion's business development efforts which involved the negotiation of strategic alliances with over 10 major pharmaceutical companies. Prior to Caprion, he was successively a management consultant with McKinsey & Company, VP of Sales & Marketing at Advanced Bioconcept Ltd. and its General Manager after its acquisition by NEN Life Sciences (now Perkin-Elmer). Martin is also a member of the Board of Directors of Victhom Human Bionics Inc. (TSX: VHB), Montreal InVivo and the Atlantic Cancer Research Institute. Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.

  George D. Lundberg, M.D. Editor, MedPage Today
A 1995 "pioneer" of the medical internet, Dr. Lundberg was born in Florida, grew up in lower Alabama and holds earned and honorary degrees from North Park College, Baylor University, the University of Alabama (Birmingham and Tuscaloosa), the State University of New York, Syracuse, Thomas Jefferson University and the Medical College of Ohio. He served 11 years in the US Army during the Vietnam War Era. Dr. Lundberg was Professor of Pathology and ran the labs at the Los Angeles County/USC Medical Center for 10 years, and was Professor and Chair of Pathology at UC Davis for 5 years.. Dr. Lundberg has worked in tropical medicine and forensic medicine in multiple countries. He is past President of the American Society for Clinical Pathology. From 1982 to 1999, Dr. Lundberg was Editor in Chief at the AMA, with editorial responsibility for its 39 medical journals, American Medical News, and various television and internet products, and the Editor of JAMA. In 1999 Dr. Lundberg became Editor in Chief of Medscape, and the founding Editor in Chief of both Medscape General Medicine and CBS HealthWatch.com. He served as the Editor in Chief of The Medscape Journal of Medicine, the original open access general medical journal, and beginning in 2006, Editor in Chief of eMedicine from WebMD, the original open access comprehensive medical textbook. A frequent lecturer and webcasting guest and host, and a member of the Institute of Medicine, Dr. Lundberg was a Professor at Harvard from 1993 to 2008. Dr Lundberg is now Editor in Chief, Cancer Commons; Editor at Large, MedPage Today, a Consulting Professor at Stanford and is President and Board Chair of The Lundberg Institute. In 2000, the Industry Standard dubbed Dr. Lundberg "Online Health Care's Medicine Man".
  Gail Maderis President & CEO BayBio
Gail Maderis is President & CEO of BayBio, the industry organization representing and supporting Northern California’s life science community. As a former biotech CEO, Ms. Maderis brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Ms. Maderis served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Ms. Maderis practiced management and strategy consulting with Bain & Co. She serves on the boards of BayBio, the Mayor’s Biotech Advisory Council of San Francisco and the HBS Healthcare Initiative. She received a BS in business from the UC Berkeley and an MBA from Harvard Business School.
  Clay B. Marsh, M.D. Professor of Internal Medicine, Sr Assoc VP for Health Sciences Research, Vice Dean of Research for College of Medicine, Executive Director of Center for Personalized Health Care, Ohio State University Medical Center
He is an NIH-funded investigator and his laboratory focuses on translational research in the area of macrophage biology and understanding molecular mechanisms underlying human health and wellness. Dr Marsh leads the efforts in Personalized Health Care at the Ohio State University, where he and senior leadership lead the effort in transforming health care delivery by creating pilot programs in wellness and chronic disease testing disruptive solutions that will result in lower cost and higher quality/outcomes. OSU is a partner in the Coriell Institute’s Personalized Medicine Collaborative and has recently entered a partnership with the Seattle-based Institute for Systems Biology to form the P4 Medicine Institute.

  Hugh Martin Chairman & CEO, Pacific Biosciences
Hugh Martin joined Pacific Biosciences in May of 2004. Hugh has a 25 year track record managing leading edge technologies, new ventures and high growth businesses. Previously, he was the Chairman, President and CEO of ONI Systems, a company he founded and took public in the high speed optical telecommunications business. Prior to ONI, Hugh was President and Director of 3DO, an interactive gaming company. Earlier, he ran desktop engineering at Apple Computer. He was educated at Rutgers University.
  Peter Neupert Corporate Vice President- Health Solutions Group, Microsoft Corp.
Peter Neupert returned to Microsoft Corp. in 2005 as the corporate vice president in charge of the Health Solutions Group. In his position, he is responsible for driving the company's global product and services strategy for health — specifically identifying market opportunities and investments where Microsoft can provide software innovations that empower users and enable transformation to improve health in developed and developing economies. Although Neupert began his career in technology, he became immersed in the world of health when he served as president and chief executive officer of drugstore.com Inc. from July 1998 to April 2001, and as chairman of the board of directors through September 2004. In 2000, he received an Ernst & Young Entrepreneur of the Year award for his work. Today, he is an active member of the Institute of Medicine's Roundtable on Evidence-Based Medicine and sits on the Pacific Health Summit Advisory Board. He also serves on the board of directors of the Foundation for the National Institutes of Health, the board of trustees for the Fred Hutchinson Cancer Research Center and the board of directors of GlobalScholar.com. Viewed as an industry authority, Neupert has testified before Congress on multiple occasions, including in 2009 on health information technology reform. He speaks at industry conferences on innovation and the impact and benefits of technology, and has contributed to leading publications including Health Affairs and Forbes.
  Garry Nolan, Ph.D. Professor in the Department of Microbiology and Immunology, Stanford University
Dr. Nolan is a tenured Professor in the Department of Microbiology and Immunology at Stanford University. He has published over 140 articles (biochemistry, gene cloning and characterization, virology immunology, transcriptional biology, bioinformatics, and signaling). He holds over a dozen patents in the biotechnology arena, and was honored as one of the top 25 inventors at Stanford University. He was the scientific founder, and was Chair of the scientific advisory board of Rigel Pharmaceuticals (a NASDAQ company); was a co-founder of the limited liability company that led to the creation of CellGate, a drug delivery company; and is the scientific Founder and Chairman of the SAB of Nodality, Inc., a venture funded company researching personalized diagnostics based on single cell interrogations of signaling networks in diseased cells. Dr. Nolan’s laboratory at the Stanford University School of Medicine focuses on the analysis of biological events at the single cell level using novel genetic and FACS-based approaches at the intersection of immunology, autoimmunity, biochemistry, and cancer. Dr. Nolan received his Ph.D. in Genetics at Stanford University under the mentorship of Leonard and Leonore Herzenberg (co-developers of the Fluorescence Activated Cell Sorter) where he worked on the cloning of CD8 and development of the first single cell reporter gene assays.  Dr. Nolan did his postdoctoral work in the laboratory of Nobelist David Baltimore at MIT. While working in the Baltimore lab, Dr. Nolan conceived and then co-developed the 293-based retroviral systems that are now a mainstay of retroviral and lentiviral production in research and gene therapy.

  Carlos Pena, Ph.D. Director of Emerging Technology Programs, FDA
Dr. Carlos Peña is Director of Emerging Technology Programs in the Office of the Chief Scientist, Office of the Commissioner, at the U.S. Food and Drug Administration (FDA). He currently serves a lead role in the development of the agency’s position and current thinking on science, research, and policy needs for emerging technology areas, with an emphasis on nanotechnology. His position includes service on the FDA Nanotechnology Task Force composed of key officials across the agency and establishing and enhancing partnerships with national and international regulatory agencies as well as other stakeholders focused on nanotechnology. He also serves as Chair of the FDA Standards Committee, a committee dedicated to ensuring effective participation by FDA in the development of both domestic and international standards relevant to emerging technologies and other product areas. Before joining FDA, Dr. Peña served at the National Institute of Neurological Disorders and Stroke, National Institutes of Health. He completed his neurosciences doctoral training at Case Western Reserve University in Cleveland, Ohio. Prior to graduate school, he attended the University of Connecticut for the Masters in Comparative Physiology, and the City College of New York, City University of New York, where he received a Bachelors specializing in Developmental Biology.

Clifford Reid, Ph.D Chairman, President & CEO, Complete Genomics
Dr. Clifford Reid is Chairman, President and Chief Executive Officer of Complete Genomics (NASDAQ: GNOM) and has over 25 years of experience in startup and growth companies managing the commercialization of innovative, unstructured data management technologies. In 1995, he was the founding chairman and chief executive officer of Eloquent, Inc., a digital video communications company that he took public in 2000 (NASDAQ: ELOQ) and sold in 2003. In 1988, he was the founding vice president of product development at Verity (NASDAQ: VRTY), an enterprise text search engine company that was subsequently sold to Autonomy for $500M. Cliff earned a B.S. in physics from the Massachusetts Institute of Technology (MIT), an M.B.A. from the Harvard Business School and a Ph.D. in management science and engineering (MSE) from Stanford University.
  Renee A. Reijo Pera, Ph.D. Professor/Director, Center for Human Embryonic Stem Cell Research and Education Institute for Stem Cell Biology & Regenerative Medicine,Stanford University School of Medicine
Dr. Reijo Pera is Director of the Stanford University Center for Human Embryonic Stem Cell Research and Education. She received her PhD from Cornell University and was a Damon Runyon Fellow in Human Genetics, at the Whitehead Institute at MIT, before joining the faculty at UCSF in 1997. She was recruited to Stanford University to direct the Center for Human Embryonic Stem Cell Research and Education in April 2007. She has received numerous awards for her work including the American Stem Cell Research Foundation Award, Outstanding Faculty Mentor Award, American Society for Reproductive Medicine Bruce Stewart Award, and was cited by Newsweek magazine as one of twenty influential women in the USA for her work in understanding human development and Time Magazine recognized her laboratory for one of the top ten “medical breakthroughs of 2010.” Her laboratory is focused on understanding how cell fate decisions are made in the embryo, in particular how particular cell lineages are formed from pluripotent stem cells.

  Peter Schad Director of MEGEH, RTI International

Dr. Schad has over 20 years experience in the areas of biotechnology including business development, genomics, as well as other “omics”, personalized medicine, translational medicine infectious disease, molecular biology, bioinformatics, medical informatics, electronic medical records, genetics, oncology, target validation, biomarker discovery, and in silico biology. Currently, Dr. Schad is the Director of Molecular Epidemiology, Genomics, Environment and Health, MEGEH at RTI providing business and scientific leadership to an interdisciplinary scientific group, as well as developing a “in silico” computational biology program to look at large desperate biological data sets utilizing non-statistical methods. Dr. Schad currently sits of several ad hoc NIH study sections for NCI, NIAID, NIRR, NIDCR and several Scientific Advisory Boards as well as elected to the Genetics and Environmental Mutagenesis Society Board of Directors

  Randy Scott, Ph.D. Executive Chairman, Genomic Health
Randy Scott, Ph.D. has served as Executive Chairman since January 2009. Prior to serving as Chairman, Randy served as Chairman and Chief Executive Officer from August 2000 through January 2009. Randy was a founder of Incyte Corporation, a genomic information company, and served Incyte in various roles, including Chairman of the Board from August 2000 to December 2001, President from January 1997 to August 2000 and Chief Scientific Officer from March 1995 to August 2000. Randy holds a Bachelor of Science degree in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
  Michael Shuster, Ph.D. IP Partner & Life Sciences Group Co-chair, Fenwick & West LLP

Dr. Shuster provides strategic intellectual property legal services to biotechnology and chemical/pharmaceutical companies. His practice includes patent prosecution, portfolio analysis, due diligence, litigation and opinion work. His clients include start-up and established biotechnology companies, venture capital firms and research universities and hospitals. Dr. Shuster’s career experience has included graduate research in the laboratory of Professor Eric Kandel at Columbia University as part of a team focused on discovery of mechanisms by which short-term memories are stored, research for which Professor Kandel was awarded the 2000 Nobel Prize in Medicine. Dr. Shuster then moved to the Department of Biochemistry and Biophysics at the University of California, San Francisco, where he pursued his interests in ion channel biophysics and protein structure. Dr. Shuster received his B.A. from Brandeis University in 1981, magna cum laude and his Ph.D. from Columbia University in 1986. He received his J.D. cum laude from the University of San Francisco School of Law in 1997. In 2009, Dr. Shuster was listed as one of the Daily Journal's Top 25 Intellectual Property Portfolio Managers.

  Michael Snyder, Ph.D. Stanford W. Ascherman Professor and Chair of Genetics & Director of Center of Genomics and Personalized Medicine, Stanford University
Michael Snyder is the Stanford W. Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine at Stanford University. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and currently carries out a variety of projects in the areas of genomics and proteomics both in yeast and humans. His laboratory built the first proteome chip for any organism and the first high resolution tiling array for the entire human genome. The Snyder laboratory sequenced the first genome (Acinetobacter) using high throughput DNA sequencing technologies, and invented and RNA-Sequencing and Paired End-Sequencing using these technologies. Dr. Snyder co-founded Protometrix (now part of Invitrogen), Affomix and Metagenomix. He is the recipient of the Connecticut Medal of Science and the Pioneer Award in Proteomics.
  Jay M. Tenenbaum, Ph.D. Chairman, CEO, and Chief Scientist, CollabRx
Jay M. ("Marty") Tenenbaum is the founder and Chairman of CollabRx. Dr. Tenenbaum brings to CollabRx the unique perspective of a world-renowned Internet commerce pioneer and visionary. He was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993) and Internet auction (1993). In 1994, he founded CommerceNet to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. Dr. Tenenbaum joined Commerce One in January 1999, when it acquired Veo Systems. As Chief Scientist, he was instrumental in shaping the company's business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon's new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.
  Vance Vanier, M.D. CEO & President, Navigenics
Vance Vanier, M.D. is the CEO and President of Navigenics. Dr. Vanier has spent the last decade of his career as a leader in the field of prevention and personalized medicine. After working as an emergency physician on the front lines of medicine and observing first hand the overwhelming need for new preventive technologies, Dr. Vanier became a partner in the life sciences practice at Mohr Davidow Ventures (MDV). At MDV, Dr. Vanier invested in and guided groundbreaking companies in the molecular and electrical diagnostic space including iRhythm, CardioDx, and Crescendo Biosciences. Recognizing the early promise of preventive genomics, he joined Navigenics in early 2008 as the company’s first Chief Medical Officer. Dr. Vanier created a vision for Navigenics built around a powerful idea - that the most effective and responsible way to introduce preventive genomic testing to the public was with the support and partnership of corporate medical directors, medical centers, and physician offices, in addition to Navigenics’ own team of Genetic Counselors. Within two years, he built a series of clinical collaborations and distribution relationships that have made Navigenics the #1 physician endorsed company in the preventive genomics space. These achievements include orchestrating the Scripps Genomic Health Initiative, one of the largest behavioral genomics initiative in the U.S., partnering with premier national physician groups such as MDVIP with its 100,000 patients, and building a network of large self-insured marquee employers who are incorporating Navigenics into their wellness and benefit programs. In further developing these and future partnerships, Dr. Vanier is committed to the belief that the transformative value of preventive genomics lies in its ability to motivate behavior change and medical compliance.
  Sheila Walcoff Partner, McDermott Will & Emery LLP
Sheila D. Walcoff is a partner in the Washington DC office of the law firm of McDermott Will & Emery LLP and a member of the Firm’s Health Industry Advisory Group and co-leads the Life Sciences/Medical Products Government Strategies Team. Previously, Ms. Walcoff served as Counselor to the Secretary of the U.S. Department of Health and Human Services (HHS), Associate Commissioner for External Affairs at the Food and Drug Administration (FDA) and the health policy team leader/senior health policy advisor to a 2008 presidential campaign.  She also has significant legislative strategy and advocacy experience and served as the majority counsel to the U.S. House of Representatives Armed Services Committee.  Her ongoing pro bono work includes legislative and policy counsel to a national eating disorder association.  Ms. Walcoff serves on the HHS Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS), the Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation (CBI) Strategy and Policy Council, and  the Board of the Friends of the National Zoo (FONZ).
  Anne Wojcicki President and Co-Founder, 23andMe
Anne brings to 23andMe a 10-year background in healthcare investing, focused primarily on biotechnology companies. Anne left the investing world with the hope that she could have a positive impact on research and medicine through 23andMe. From her vantage point, Anne saw a need for creating a way to generate more information - especially more personalized information - so that commercial and academic researchers could better understand and develop new drugs and diagnostics. By encouraging individuals to access and learn about their own genetic information, 23andMe will create a common, standardized resource that has the potential to accelerate drug discovery and bring personalized medicine to the public. (Plus, getting access to her own genetic information and understanding it has always been one of Anne's ambitions.) Anne graduated from Yale University with a B.S. in biology.
  Judging Panel
  Rowan Chapman, Ph.D. Partner, MDV
Rowan Chapman joined MDV in 2001 to focus on life science investments. Her interests lie in the translation of complex data and technology to innovative products that impact drug and biofuel discovery, personalized medicine and healthcare decision making. Leveraging her business and technical experience as well as industry relationships she partners closely with entrepreneurs to help develop successful businesses. She partners with entrepreneurs in a "hands on" role to help get companies started and financed. Rowan is a board member of iAccessCare and MLC Dx and a board observer at Artemis Health, Pacific Biosciences, Adamas Pharmaceuticals, ParAllele BioScience (acquired by Affymetrix) and Tethys Biosciences. Rowan is also a member of the Personalized Medicine Coalition. Prior to joining MDV Rowan held the position of director of business development at Rosetta Inpharmatics (acquired by Merck) where she established collaborative partnerships with organizations in the pharmaceutical, agricultural and biotech fields as well as among various research institutions. Previously, Rowan held the position of marketing manager at Incyte Genomics. Rowan holds a Ph.D. in cellular and molecular biology from the MRC Laboratory of Molecular Biology in Cambridge University, UK where she also earned a bachelor's degree with first class honors in Biochemistry. She served postdoctoral fellowships at the University of California, San Francisco, as well as at the MRC-Laboratory of Molecular Biology at Cambridge. Prior to her work in industry, she authored or co-authored more than a dozen articles and patents.
  Paul Hastings President & CEO, OncoMed Pharmaceuticals, Inc.
Mr. Hastings brings more than 20 years of experience as a biotechnology and pharmaceutical industry executive. He has served as President and CEO of OncoMed Pharmaceuticals since January 2006. Prior to joining OncoMed, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr Hastings was recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2009), and served on the boards of ViaCell (sold to Perkin-Elmer in 2008), and Cerimon Pharmaceuticals. He is currently Chairman of the Board of the Bay Area Biosciences Association (Bay Bio) and serves on the executive committee of the board of directors of the Biotechnology Industry Association. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.
  John Steuart Managing Director, Claremont Creek Ventures
John has spent the last 20 years managing, building and investing in technology and life science companies. John focuses on the intersection of the information technology and life sciences markets including bioinformatics, molecular diagnostics, genomics, proteomics software and instrumentation for med-tech industries. John serves on the board of directors of Arcxis, Tibion, Fluxion, Gene Security Network & Wired Benefits. Early in his career, he joined Alafi Capital, an Emeryville-based venture firm specializing in early-stage biomedical companies, where he served as an officer of the General Partner. At Alafi, John lead investments in more than a dozen successful start-ups, and served as the senior executive and board member of various firms such as Tanox, Software Ventures, Lipomatrix, and Megan Health. In the mid-90s, together with colleague Nat Goldhaber, John helped start Cybergold, an Internet marketing and payments company, serving as the early COO and CFO through its IPO, merger with Mypoints and sale to United Airlines. John continued with the Mypoints unit of United serving as the Senior Vice President of Strategic Partnerships.
    Judging Panel Moderator
  Melinda Richter Founder & CEO, Prescience International
Melinda Richter is the founder and CEO of Prescience International, a firm dedicated to the commercialization of science and technology through consulting on, starting and managing research centers, incubators, foundations and institutes such as the San Jose BioCenter, the San Francisco Innovation Center, the San Diego BioCenter, the Seattle BioCenter, the Environmental Business Cluster (EBC), the UC Berkeley BioExec Institute. Prescience also provides commercialization services to key government research agencies like the National Cancer Institute and the California Energy Commission; in helping get their grantees investment. The San Jose BioCenter model, a science and technology incubator that provides specialized facilities, capital equipment, laboratory support and business development services to life science and cleantech companies, has the 2009 NBIA Randall Whaley Award for Best Incubator of the Year and also the 2009 NBIA Technology Incubator of the Year Award. In that regard, the BioCenter has become the best-practice model for many entities that wish to capitalize on innovation, ranging from economic development agencies to big corporate players. Ms. Richter currently sits on the governing board of the National Business Incubation Association and the boards of University of California Berkeley’s Haas School of Business BioExec Institute and San Jose State University’s Masters of Biotechnology Program. Ms. Richter holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an M.B.A. from INSEAD in France.
    Tutorial Speakers
  Joseph Bach Partner, Nixon Peabody
Mr. Bach has more than a decade of legal experience in all aspects of intellectual property law, including patent prosecution and litigation. Joseph has developed methodologies for, and counsels clients on, efficiently building and managing effective patent portfolios. Joseph has successfully handled and managed cases in a broad range of technologies and has litigation experience before the International Trade Commission and federal courts. Joseph was formerly Senior Director of Intellectual Property at Applied Materials, where he was responsible for all aspects of the company's intellectual property internationally. He hold a law degree from the Duke University School of Law and a B.S. Engineering and Applied Science from California Institute of Technology (Caltech).
  Maureen Cronin, Ph.D. Molecular Diagnostics and Personalized Medicine Expert

Dr. Cronin is an internationally recognized leader in high complexity molecular diagnostic assay technology research, development and validation. In her former role as Vice President of Translational Research at Genomic Health, Dr. Cronin headed the team that proved the clinical utility of performing RNA expression profiling from FFPE tumor specimens. She went on to lead development of the laboratory process and analytical assay validation of the Oncotype DX breast cancer test. Her expertise extends to identifying optimal laboratory processes and integrating them with automation systems, data management, bioinformatics and biostatistical analyses to produce fully optimized, high throughput, high-performance, innovative, first-in-class medical products performed in a regulated reference laboratory environment. Dr. Cronin brings over 20 years of R&D experience in biotechnology companies focused on applying cutting edge technology to clinical diagnostics including ACLARA BioSciences, Protogene Laboratories and, Affymetrix where she played a key role in developing DNA microarray(GeneChip®) technology. Dr. Cronin’s Ph.D. in Molecular Pharmacology is from the University of California, San Diego and her undergraduate education from the University of California, Davis.

  Michael A. Goldman, Ph.D. Department of Biology Prof. & Chair, San Francisco State University
Dr. Goldman did his undergraduate work in Biology at the University of Rochester and obtained a Ph.D. in evolutionary biology at Purdue University in 1981. He completed fellowships in Medical Genetics at Baylor College of Medicine in Houston and at the University of Washington in Seattle. He joined the faculty at San Francisco State University in 1988, where he is now Professor and Chair of the Department of Biology. He teaches human genetics at the graduate level, general genetics for biology majors, developmental biology for Cell & Molecular Biology majors, and an interdisciplinary course on the ethical issues in science and technology. Dr. Goldman's research is in chromatin structure and the regulation of gene expression during mammalian development. Of special interest is the relationship between chromosome structural elements called nuclear matrix attachment regions (MARs) as boundaries of functional chromatin domains, studied through molecular methods and bioinformatics. He sees the public understanding of science as a key need if science and society are to thrive, and has talked about various issues like stem cell biology for TV and radio call-in audiences. He has written Op-Ed pieces for the Los Angeles Times, the Sacramento Bee, and the San Francisco Chronicle as well a professional papers appearing in Science and Nature Genetics. Thinking that the public learns much about science and bioethics from fiction, he reviews novels addressing various aspects of genetic science and its implications, in venues like Nature, Science, Nature Genetics and the San Francisco Chronicle.

Richard Rava, Ph.D. President, Artemis Health
Dr. Rava comes to Artemis Health after 16 years at Affymetrix where he was a scientific co-founder and most recently Senior Vice President of Research and Development. While in various roles at Affymetrix, he led the research, development and manufacturing scale-up of the Affymetrix GeneChip® technology. He was responsible for the delivery of multiple products involving complex assays, microarrays, instrumentation and software that merged scientific technology with the needs of the gene expression, genetics research and clinical markets. Prior to joining Affymetrix, Dr. Rava served as a Senior Scientist at Affymax Research Institute. From 1990 through 1992, he served as Principal Research Scientist at the George R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology (MIT). During that time, he was also the research coordinator for the National Institute of Health Laser Biomedical Research Center at MIT. Dr. Rava has over 60 papers in refereed scientific publications and over 30 issued U.S. patents. He received his B.A. and Ph.D. in Chemistry from Rutgers University.

Jeff Shrager, Ph.D. Chief Technology Officer, CollabRx
Jeff Shrager is the CTO of CollabRx, and a consulting associate professor in the Symbolic Systems program at Stanford University. As a computational psychologist of science, Dr. Shrager seeks to understand how science works, and to build human-computer networks that facilitate discovery. Previously, Dr. Shrager co-founded several scientific-computing start-ups (including Afferent Systems, acquired by MDL), and invented BioBike, a web-based biological knowledge platform enabling biologists to develop, run, and share complex analyses of genomic information. Dr. Shrager holds degrees in computer science and cognitive neuroscience from The University of Pennsylvania and CMU, and publishes extensively in scientific computing, AI, biology, genomics, and the cognitive sciences.
  Peter J. Tonellato, Ph.D. Center for Biomedical Informatics, Harvard Medical School
Peter Tonellato is on the faculty of Harvard Medical School at the Center for Biomedical Informatics and the Department of Pathology at Beth Israel Deaconess Medical Center in Boston and at the School of Public Health, University of Wisconsin, Milwaukee, WI. Past affiliations include the Department of Mathematics, Marquette University and the Bioinformatics Research Center, Medical College of Wisconsin. Dr. Tonellato founded and was Chairman of POINTONE, a personalized medicine software company that provided genetic enabled ‘best practice’ decision support system to hospitals and health care facilities. Dr. Tonellato created and was P.I. of the Rat Genome Database, a disease-centric repository of phenotype and genetic data. Dr. Tonellato is the director of the Laboratory for Personalized Medicine (lpm.hms.harvard.edu) a joint (Harvard Medical School, Beth Israel Deaconess Medical Center, School of Public Health, UWM) lab developing strategies, methods, bioinformatic tools, and analyses to study and test the accuracy and clinical efficacy of genetic discoveries and accelerate their translation to practical clinical use.
    NCI Guest Speaker
  Andrew Kurtz, Ph.D. Office of the Director, National Cancer Institute
Dr. Kurtz has been a Program Director in the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI) for the last three years. His management portfolio includes projects focused on early-stage cancer drug development, including small molecules, biologics, and novel multifunctional therapeutics based on nanotechnology. Previously, Dr. Kurtz was a AAAS Science and Technology Policy Fellow at the NIH, during which time he served on the management team of The Cancer Genome Atlas Pilot Project and played a key role in developing several new pilot initiatives for the SBIR program at the NCI. Prior to his fellowship, Dr. Kurtz conducted basic research in DNA repair and mutagenesis for several years and also served as a Research Associate at Cedra Corporation, an Austin-based CRO that provides GLP analytical services to the biotechnology and pharmaceutical industries. Dr. Kurtz received a BS in Chemistry from The University of Texas at Austin and a PhD in Biochemistry & Molecular Biology from The University of Texas Medical Branch at Galveston.

Real Time Web Analytics